Shanghai and South San Francisco, Calif., June 26, 2025 - Mabwell (Shanghai) Bioscience Co., Ltd. (688062.SH), an innovative biopharmaceutical company, and Calico Life Sciences LLC (Calico) a biotechnology organization focused on aging and age-related diseases and founded by Alphabet Inc. and Arthur D. Levinson, Ph.D., today announced an exclusive licensing agreement for IL-11 directed therapeutics, including 9MW3811, a Phase I monoclonal antibody (mAb).

Preclinically, Mabwell has explored the therapeutic potential of 9MW3811 in age-related diseases and has conducted Phase I trials in China and Australia. 9MW3811 also has an open IND to perform a U.S. Phase I trial. Under the terms of the agreement, Mabwell will grant Calico exclusive rights to develop, manufacture, and commercialize 9MW3811 in all regions except Greater China.

About Mabwell

Mabwell (688062.SH) is an innovation-driven biopharmaceutical company with the entire value chain of the pharmaceutical industry. The company provides more effective and accessible therapy and innovative medicines to fulfill global medical needs, focusing on oncology and aging-related disease indications. Mabwell’s mission is "Explore Life, Benefit Health" and its vision is "Innovation, from ideas to reality". For more information, please visit www.mabwell.com/en.

About Calico

Calico (Calico Life Sciences LLC) is an Alphabet-founded research and development company whose mission is to harness advanced technologies and model systems to increase our understanding of the biology that controls human aging. Calico will use that knowledge to devise interventions that enable people to lead longer and healthier lives. To learn more about Calico, visit www.calicolabs.com.